From GlobeNewswire: 2025-04-21 20:00:00

Scorpius Holdings, Inc. is facing delisting proceedings from NYSE American due to low-selling price and noncompliance with timely filing criteria for the Form 10-K. The company plans to appeal the decision and remains committed to operational progress. CEO Jeff Wolf emphasizes transparency and regulatory compliance. Scorpius Holdings Inc. specializes in biologic and cell therapy development and manufacturing, offering services to pharmaceutical and biotech companies. The company aims for collaboration, high-quality manufacturing, and compliance with U.S. Securities and Exchange Commission regulations. For more information, visit www.scorpiusbiologics.com. Contact David Waldman for media and investor relations at +1 919 289 4017 or [email protected].



Read more at GlobeNewswire: Scorpius Holdings Receives NYSE American Notice of